Project Grant R21CA287157
Award Date 9/1/24
Completion Date 8/31/26
Dollars Obligated $415K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $707,798 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning April 1, 2026, and concluding March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-resistant form within months of standard-of-care treatment. The primary deliverable is...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai $683,256 under the Cancer Biology Research program (CFDA 93.396) for the project "Human-Mouse Platform for Data-Driven Patient Stratification, Target Discovery, and Validation in GBM." The award, effective May 22, 2026, with completion targeted for April 30, 2031, supports fundamental research to advance understanding of glioblastoma (GBM) heterogeneity and improve...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $399,829 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel research models for investigating sex-based disparities in glioblastoma (GBM). The award, effective July 7, 2025 through June 30, 2027, funds the creation of investigative tools and methodologies to examine how sex chromosomes and sex hormones influence GBM phenotype, proliferation, and...
- Grant Award Summary The National Cancer Institute awarded a $544,520 Project Grant to the University of Illinois (Chicago) under the Cancer Treatment Research program (CFDA 93.395) on April 7, 2026, with completion targeted for March 31, 2031. The project develops a microRNA (miRNA)-based therapeutic approach specifically targeting pediatric high-grade gliomas (PHGGs), including glioblastomas and diffuse intrinsic pontine gliomas—tumors that represent the leading cause of cancer-related...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pennsylvania a $667,041 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026, through February 28, 2031. This grant supports the validation and credentialing of patient-derived xenograft (PDX) models of hepatocellular carcinoma (HCC), with the primary objective of establishing translational relevance and reliability standards for these preclinical models. The...
- Award Summary The Medical College of Wisconsin, Inc. received a $602,121 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective June 1, 2026 through May 31, 2031. This award supports longitudinal radio-pathomic mapping research to develop advanced diagnostic techniques for predicting pathological tumor characteristics in glioblastoma using standard clinical magnetic resonance imaging (MRI). The research...
- Summary The National Cancer Institute awarded The Methodist Hospital Research Institute a $415,257 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 9, 2026, to develop image-guided adaptable chimeric antigen receptor (CAR) T cell therapy for solid tumors. The project addresses critical limitations in current CAR T cell treatments, including tumor relapse, antigen escape, T cell exhaustion, and severe toxicities. The research will create a universal,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $100,228 to Weill Medical College of Cornell University under the Cancer Research Manpower program (CFDA 93.398) for research titled "Spatial and Clonal Dynamics in Glioblastoma: Disentangling Drivers of Migration and Stemness." The award, obligated on December 1, 2026, with completion targeted for April 5, 2029, supports investigator-initiated biomedical research training aligned with the...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...